

PATHFINDER
TECHNOLOGIES
Visualization | Planning | Navigation


April 4, 2013

Steven D. Singleton
Limestone Fund, LLC
1600 Division Street, Suite 580
Nashville, TN 37203

Dear Mr. Singleton:

Pursuant to Subordinated Convertible Promissory Note entered into as of March 18, 2013, by and between Limestone Fund, LLC and Pathfinder Therapeutics, Inc., a Delaware Corporation, Limestone Fund, LLC, has purchased a note convertible into Series B2 Preferred Stock of Pathfinder Therapeutics, Inc. for \$60,000.

Thank you.


Johnny Drake
Chief Commercial Officer